Claudin protein expression level determination is a laboratory testing service used to quantitatively or semi-quantitatively measure the expression of claudin family proteins, the core structural components of epithelial tight junctions, in biological samples. Accurate assessment of claudin expression is essential for cancer diagnosis, patient stratification for targeted therapies such as CLDN18.2-directed antibodies, and research into barrier dysfunction in inflammatory, renal, and malignant diseases.
Technical Overview
Claudins are a family of at least 27 integral membrane proteins (CLDN1 through CLDN27) that serve as the principal structural and functional components of tight junctions in epithelial and endothelial cell sheets. Each claudin molecule contains four transmembrane domains, two extracellular loops, and cytoplasmic N- and C-terminal tails. Through homo- and heterotypic interactions, claudins form the paracellular seal that regulates ion selectivity, solute permeability, and cell polarity, effectively acting as the gatekeeper and fence of the intercellular barrier.
Dysregulation of claudin expression is strongly associated with human disease. Altered claudin profiles contribute to barrier breakdown in inflammatory bowel disease, renal tubular dysfunction caused by CLDN16 or CLDN19 mutations, and tumor progression, metastasis, and proliferation in carcinomas of the stomach, breast, pancreas, ovary, colon, and lung. Notably, CLDN18.2 has emerged as a clinically actionable target in gastric and gastroesophageal junction adenocarcinoma, where positivity guides treatment with targeted monoclonal antibodies such as zolbetuximab. Consequently, reliable determination of claudin expression levels at both the mRNA and protein levels has become a critical requirement in precision oncology and translational research.
Claudin protein expression level determination encompasses a panel of validated analytical platforms, including immunohistochemistry (IHC), Western blotting, quantitative real-time PCR (RT-qPCR), flow cytometry, immunofluorescence, RNA in situ hybridization, and enzyme-linked immunosorbent assay (ELISA). Each method addresses different biological questions, sample types, and throughput needs, and the selection of an appropriate platform depends on the intended clinical or research objective.
Testing Samples
Formalin-Fixed Paraffin-Embedded (FFPE) Tissue
FFPE tissue sections are the standard specimen type for clinical claudin testing, particularly for CLDN18.2 companion diagnostics in gastric cancer. Archival surgical resection specimens and biopsy cores are both acceptable, provided that fixation follows standardized protocols (typically 10% neutral buffered formalin for 6 to 48 hours) to preserve antigenicity. Sections of 3 to 5 micrometers thickness are prepared on positively charged slides for IHC or RNA in situ hybridization assays.
Fresh or Frozen Tissue
Fresh tissue snap-frozen in liquid nitrogen or embedded in optimal cutting temperature (OCT) compound offers superior preservation of protein and RNA integrity. Frozen specimens are preferred for Western blotting, RT-qPCR, flow cytometry on dissociated cells, and proteomics applications where post-translational modifications or mRNA quantification are of interest.
Blood, Plasma, and Serum
Circulating claudin fragments and extracellular vesicle-associated claudins can be measured in peripheral blood using ELISA or flow cytometry-based assays. These liquid biopsy approaches are primarily used in research settings for treatment monitoring, minimal residual disease evaluation, and pharmacodynamic biomarker studies, as soluble claudin levels may reflect tumor burden and junctional remodeling.
Cell Lysates and Cultured Cells
Cultured epithelial, endothelial, and tumor cell lines, organoids, and primary cells are routinely analyzed to characterize claudin expression profiles, evaluate gene knockdown or overexpression, screen pharmacological modulators of tight junction assembly, and validate antibody specificity. Both whole-cell lysates and membrane-enriched fractions are suitable for protein-level quantification.
Urine and Other Body Fluids
Urine, cerebrospinal fluid, bronchoalveolar lavage, and ascites may be collected for investigating renal tubular transport disorders, blood-brain and blood-air barrier integrity, and malignant effusions. Sample volumes, preservatives, and centrifugation conditions are specified according to the downstream assay requirements.
Testing Items
Claudin expression determination can be performed for individual family members or as multiplex panels covering multiple targets. Commonly requested testing items include:
- CLDN1: epithelial barrier maturation, colorectal and hepatocellular carcinoma research, skin barrier studies
- CLDN2: cation-selective pore-forming claudin, relevant to leaky epithelia, renal magnesium handling, and colon tumorigenesis
- CLDN3 and CLDN4: ovarian, breast, and pancreatic cancer markers; receptors for Clostridium perfringens enterotoxin (CPE)
- CLDN5: endothelial blood-brain barrier integrity and vascular permeability assessment
- CLDN7: paracellular sealing in epithelia; prognostic marker in breast and colorectal cancer
- CLDN16 and CLDN19: renal tubular magnesium and calcium reabsorption; mutation and expression analysis for hypomagnesemia syndromes
- CLDN18.2: companion diagnostic and pharmacodynamic marker for targeted therapy in gastric, gastroesophageal junction, pancreatic, and other advanced solid tumors
- Claudin mRNA panels: quantitative transcriptional profiling of the full claudin family by RT-qPCR or RNA sequencing
- Protein quantification panels: absolute or relative protein abundance by Western blot densitometry, ELISA, or targeted mass spectrometry
Deliverables typically include stained slides with pathologist-verified interpretation, digital images, quantitative signal data normalized to appropriate loading or reference controls, and a consolidated technical report with methodology, controls, and assay limitations.
Testing Methods
Immunohistochemistry (IHC)
IHC is the gold-standard platform for clinical claudin determination, particularly for CLDN18.2. Validated claudin-specific antibodies are applied to FFPE sections, and antigen-antibody binding is detected via chromogenic or fluorescent visualization. Membranous staining pattern, staining intensity (0 to 3+), and the percentage of positive tumor cells are scored by qualified pathologists. A commonly accepted positivity criterion for CLDN18.2 is moderate-to-strong membranous staining in at least 75% of viable tumor cells, although scoring thresholds may vary by protocol and regulatory jurisdiction. IHC preserves tissue architecture and enables direct correlation of expression with tumor morphology.
Western Blotting
Western blot analysis separates denatured proteins by SDS-PAGE, transfers them to membranes, and detects claudin bands with specific antibodies followed by chemiluminescent or fluorescent readout. Quantification is performed by densitometry normalized against housekeeping proteins such as beta-actin, GAPDH, or total protein stain. This method provides information on molecular weight, isoforms, and approximate abundance, making it valuable for mechanistic studies and antibody validation.
Quantitative Real-Time PCR (RT-qPCR)
RT-qPCR measures claudin mRNA transcript levels with high sensitivity and dynamic range. RNA extracted from tissue or cells is reverse-transcribed, and target amplification is monitored with fluorescent probes or SYBR Green chemistry. Expression is quantified using the delta-delta Ct method relative to reference genes such as GAPDH, ACTB, or RPLP0. RT-qPCR is well suited for high-throughput screening of the entire claudin family and for detecting transcriptional changes following experimental interventions.
Flow Cytometry
Flow cytometric analysis detects claudin proteins on the surface or within permeabilized cells using fluorochrome-conjugated antibodies. This approach quantifies expression at the single-cell level, resolves heterogeneous subpopulations, and supports multiparameter phenotyping when combined with lineage and activation markers. It is particularly useful for evaluating circulating tumor cells, dissociated tumor suspensions, and engineered cell products.
Immunofluorescence and Confocal Microscopy
Immunofluorescence localizes claudin proteins at tight junction structures with subcellular resolution. Co-staining with junctional markers such as ZO-1, occludin, and E-cadherin allows assessment of tight junction assembly, continuous belt-like organization, and membrane trafficking. Confocal microscopy and quantitative colocalization analysis provide powerful tools for barrier biology research.
ELISA and Immunoassays
Sandwich ELISA and chemiluminescent immunoassays quantify soluble or extracted claudin proteins in plasma, serum, urine, conditioned medium, and lysates. Calibration curves generated with recombinant standards enable absolute quantification in pg/mL to ng/mL ranges, supporting longitudinal pharmacodynamic monitoring and biomarker development.
RNA In Situ Hybridization
RNA ISH detects claudin transcripts directly in tissue sections using hapten-labeled probes with signal amplification. This method maintains spatial context while achieving single-transcript sensitivity, offering a complementary or confirmatory tool when protein epitopes are compromised by fixation or when antibody specificity is uncertain.
Applications
Claudin expression determination supports a broad spectrum of clinical and translational objectives:
- Precision oncology: identification of CLDN18.2-positive patients with gastric, gastroesophageal junction, or pancreatic adenocarcinoma for eligibility assessment and treatment monitoring with CLDN18.2-targeted antibody therapies
- Companion diagnostics and clinical trials: analytical validation of claudin assays as biomarker-stratified enrollment criteria in registrational studies
- Tumor subtyping and prognosis: characterization of claudin-low phenotypes in breast cancer, mesenchymal signature evaluation, and prognostic stratification in colorectal, ovarian, and hepatobiliary malignancies
- Barrier dysfunction research: investigation of epithelial and endothelial permeability in inflammatory bowel disease, celiac disease, atopic dermatitis, acute lung injury, and sepsis models
- Renal pathophysiology: evaluation of CLDN16, CLDN19, and related claudins in hereditary hypomagnesemia, Bartter-like syndromes, and drug-induced tubulopathy
- Drug development: screening of tight junction modulators, claudin-targeted therapeutics, antibody-drug conjugates, CAR-T cell constructs, and enterotoxin-based agents; assessment of biodistribution and target engagement
- Toxicology and safety: monitoring of junctional integrity in organotypic models, gut-on-chip systems, and inhalation or dermal exposure studies
FAQ
What is the recommended sample type for CLDN18.2 testing?
FFPE tumor tissue from surgical resection or endoscopic biopsy is the standard specimen. Biopsy samples are acceptable if they contain sufficient viable tumor cells; primary and metastatic lesions generally show concordant expression, but testing of the most recently obtained lesion is recommended.
How are IHC results for claudin expression interpreted?
Results are interpreted by combining staining intensity (0, 1+, 2+, 3+) with the proportion of positive tumor cells, emphasizing the completeness of membranous staining. Positive and negative controls, including validated CLDN18.2-expressing gastric cancer tissue, are run in parallel to ensure assay validity.
What is the typical turnaround time?
IHC-based determination is generally completed within 3 to 7 working days after sample receipt, whereas RT-qPCR, Western blotting, and multiplex panel projects typically require 1 to 2 weeks depending on sample volume and complexity.
Can mRNA and protein results differ, and which should be trusted?
Discrepancies can occur because claudin proteins are regulated by translation efficiency, membrane trafficking, and degradation. For clinical decision-making, protein-level IHC is prioritized because drug binding depends on the extracellular domain of the membrane-localized protein; mRNA assays are best used for screening and mechanistic studies.
Which claudin family members are most relevant to drug development?
CLDN18.2 is the most clinically advanced target, followed by CLDN4 and CLDN3 in ovarian and pancreatic cancer, CLDN6 in testicular and ovarian tumors, and CLDN1 in colorectal cancer. CLDN18.1 splice variant cross-reactivity is a key specificity consideration when evaluating candidate antibodies.
What quality measures are implemented to ensure reliable results?
Laboratories employ antibody validation against knockout and overexpression controls, standardized antigen retrieval and staining protocols, replicate analyses, reference material comparison, pathologist review, and participation in external proficiency testing programs where available.